Drug updated on 11/9/2023
|Tablet (oral; 100 mg)
|Sexual Disorder Agents
|Ongoing and Completed Studies
- For the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.
Product Monograph / Prescribing Information
|Addyi (flibanserin) Prescribing Information.
|Sprout Pharmaceuticals, Inc., Raleigh, NC
Systematic Reviews / Meta-Analyses
|Female sexual dysfunction: a systematic review of outcomes across various treatment modalities.
|Sexual Medicine Reviews
|Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials
|Journal of women's health
Clinical Practice Guidelines
|The International Society for the Study of Women's Sexual Health Process of Care for management of hypoactive sexual desire disorder in women.
|Mayo Clinic Proceedings